Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Full Steam Ahead For Exelixis' Phase III Glioblastoma Trial

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

The study of about 400 patients will not be open to patients who have received Roche/Genentech's Avastin, which was approved in 2009 for recurrent disease.

You may also be interested in...



Role of Newly Approved Avastin In Glioblastoma Divides Experts

The fact that Avastin's clearance under FDA's accelerated approval pathway rested on two single-arm trials raises questions for some about whether it can really be considered the standard of care, yet it is anecdotally reported as coming into ever wider use in the U.S. ("Avastin Clinical Benefit Trumps Anti-tumor Effect In Glioblastoma, ODAC Says," "The Pink Sheet" DAILY, April 6, 2009). Phase III trials are under way, but results won't become available until 2014.

FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011

Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011

Provenge Paradox Sparks New Thinking About Immunotherapy Trials, Clinical Care

The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class

Topics

UsernamePublicRestriction

Register

PS004553

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel